Telix Pharmaceuticals (ASX:TLX) Big Upside, but Only if the FDA Says Yes.

Telix Pharmaceuticals, The Clock Is Now Running

For many investors following Telix Pharmaceuticals (ASX:TLX), the story has been the sharp fall in the share price after the FDA setback, with the stock dropping almost 70% from its high to its low. What is becoming clearer now is that the company is taking real steps toward getting its final NDA through the process.

It is important to understand what accepted means here. Accepted does not mean approved. It means the FDA has reviewed the submission at the initial stage and determined that the application is complete enough to move into a full scientific review. In other words, the data package is in order and the formal assessment process is now underway.

That is an important step because it takes the application beyond the procedural risk of being rejected again at filing. Telix has said it expects to hear back by 11 September this year.

A standard NDA review usually takes around 10 to 12 months, while a Fast Track designation can shorten that to around six months. Pixclara is now moving through that expedited Fast Track pathway following the resubmission on 13 March.

Another supportive factor is that the FDA already has an Expanded Access Program in place for Pixclara. That means US patients can access the drug on a compassionate basis before formal approval. Existing clinical use in real-world US settings does not guarantee approval, but it is still a positive sign as the review process continues.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

The First and Only, A Powerful Position

If the NDA is approved by September, we believe Telix could see a major re-rate. Its precision imaging business, especially Illuccix, is already seeing strong commercial adoption and generating high-margin revenue.

Pixclara would be the first FDA-approved amino acid PET imaging agent for brain cancer in the US. That is important because Telix would not be entering a crowded market. It would be entering a space with very limited direct competition, which should give the company meaningful pricing power for some time.

Telix also has a seven-year legally protected monopoly on Pixclara for glioma imaging in the US. Even if competitors try to enter, they still face a long approval pathway. In practical terms, this is not a market Telix would be stepping into and fighting for straight away. It is a market the company would effectively control.

That is why we think approval would represent pure upside for the stock.

Pixclara Isn’t Just an Imaging Agent

Telix’s goal with Pixclara is not limited to imaging alone. The company’s therapy candidate, which is still in development, targets the same LAT1 protein, the L-type amino acid transporter 1, which is expressed in brain cancer.

That is deliberate. If the imaging agent can identify patients with high LAT1 expression, the therapy can then use that same target to deliver a lethal dose of radiation directly to the tumour site. That is telix current target using isotopes as very precise directed radiation.

This is knon as the theranostic model, scan and treat using the same biological target. It is the same basic architecture that made Novartis’ PSMA-targeting prostate cancer platform so commercially successful.

That is why Pixclara matters beyond being a standalone imaging product. Its approval would help create the companion diagnostic pathway for TLX101-Tx, the therapy currently being advanced through the pivotal IPAX-BrIGHT trial.

That is a big reason why so much of Telix’s value is now being driven by expectations around this part of the pipeline.

Our investment view, the Upside Catalyst With Eyes Open on Risk

This is one of the clearest regulatory announcements Telix has made in a while. The FDA has now formally accepted the Pixclara resubmission and set a hard decision date. If Telix gets the green light, we would expect a substantial re-rate in the stock. If it does not, the downside is equally clear and another sharp decline would be likely.

The commercial opportunity is also structurally attractive. Pixclara would enter as the first mover in a category with no existing competition, seven years of exclusivity, guideline-supported clinical use internationally, and backing from leading neuro-oncology centres.

The addressable market is not as large as prostate cancer, but that does not mean it lacks value. Glioma is a smaller niche, yet Pixclara would not be facing generic competition or meaningful pricing pressure for seven years. In a specialised oncology PET market, that creates the potential for a durable, high-margin revenue stream.